7.2 Healthcare Personnel Immunizations & Screening

7.2 Healthcare Personnel Immunizations & Screening

Quick Answer: The CDC Advisory Committee on Immunization Practices (ACIP) mandates rigorous immunization and screening protocols for healthcare personnel (HCP). Primary requirements include Hepatitis B vaccination with post-vaccination serologic testing (PVST) confirming anti-HBs ≥10 mIU/mL 1–2 months post-series. Non-responders must undergo a second vaccine series; persistent non-responders (<10 mIU/mL after 6 doses) are deemed non-responders needing HBIG upon exposure. Immunity for MMR and Varicella requires 2 documented vaccine doses or positive IgG titers (birth before 1957 is NOT sufficient for HCP during outbreaks). Tdap is required once, plus boosters every 10 years. Influenza requires annual vaccination. Baseline TB screening mandates an IGRA blood test or two-step TST plus risk assessment; routine annual rescreening is discontinued for low-risk settings.

Healthcare personnel (HCP) are at continuous risk of acquiring and transmitting vaccine-preventable diseases in clinical settings. Comprehensive immunization and occupational health screening programs protect healthcare workers, preserve workforce stability, and prevent nosocomial transmission to vulnerable patients. Infection Preventionists work closely with Employee Health departments to establish policies compliant with CDC/ACIP guidelines and OSHA standards.

---

Regulatory & ACIP Framework for Healthcare Personnel Immunization

Under OSHA standard 29 CFR 1910.1030, employers must offer the Hepatitis B vaccine series free of charge to all employees who have occupational exposure to blood or other potentially infectious materials (OPIM) within 10 working days of initial assignment. If an employee declines, they must sign a formal OSHA Mandatory Declination Statement, though they retain the right to request and receive the vaccine at any future date without cost.

The CDC's Advisory Committee on Immunization Practices (ACIP) establishes evidence-based immunization standards specifically tailored for HCP. ACIP categorizes vaccines into those strongly recommended for all healthcare personnel and those indicated in specific clinical situations.

---

Hepatitis B Vaccine Series & Serologic Thresholds

Hepatitis B virus (HBV) immunization is a cornerstone of occupational health. All HCP with potential blood exposure must receive the vaccine series and undergo post-vaccination serologic testing (PVST).

Vaccine Options & Schedules

• 3-Dose Standard Series (Engerix-B, Recombivax HB): Administered at 0, 1, and 6 months.
• 2-Dose CpG-Adjuvanted Series (Heplisav-B): Administered at 0 and 1 month (approved for adults ≥18 years; offers higher seroprotection rates in shorter timeframes).

Post-Vaccination Serologic Testing (PVST)

• Timing: Perform quantitative hepatitis B surface antibody (anti-HBs) testing 1 to 2 months after the final dose of the vaccine series.
• Protective Threshold: An anti-HBs concentration of ≥10 mIU/mL indicates adequate immunity (seroprotection).
• Long-Term Protection: Immunocompetent HCP who achieve anti-HBs ≥10 mIU/mL possess long-term immunological memory and protection against acute disease and chronic infection. Routine booster doses or periodic anti-HBs testing are NOT recommended for immune individuals.

Management of Non-Responders (Anti-HBs <10 mIU/mL)

If post-vaccination testing shows anti-HBs <10 mIU/mL:

1. Second Vaccine Series: Administer a second complete 3-dose HBV series (or 2-dose Heplisav-B series).
2. Re-Test: Test anti-HBs 1 to 2 months after the final dose of the second series.
3. Persistent Non-Responders: If anti-HBs remains <10 mIU/mL after a total of 6 doses (two 3-dose series), the employee is classified as a Vaccine Non-Responder.
4. Non-Responder Management: Test for HBsAg and total anti-HBc to rule out underlying chronic HBV infection. Non-responders must be counseled that they remain susceptible to HBV infection and require Hepatitis B Immune Globulin (HBIG) within 24 hours of any occupational exposure to HBsAg-positive blood.

---

MMR (Measles, Mumps, Rubella) & Varicella Immunity Criteria

Preventing transmission of airborne and droplet exanthems requires documented immunity among all healthcare staff.

Measles, Mumps, and Rubella (MMR)

Presumptive evidence of immunity for HCP requires one of the following:

• Written Documentation of Vaccination: 2 valid doses of live MMR vaccine administered at least 28 days apart.
• Laboratory Evidence of Immunity: Positive serologic IgG titers for Measles, Mumps, and Rubella.
• Laboratory Confirmation of Disease: Documented history of lab-confirmed infection.
• Critical Note on Birth Year: While birth before 1957 is generally considered presumptive evidence of immunity for the general public, ACIP recommends that healthcare facilities consider vaccinating unvaccinated HCP born before 1957 who lack laboratory evidence of immunity, especially during outbreaks.

Varicella (Chickenpox)

Presumptive evidence of varicella immunity requires:

• Documentation of Vaccination: 2 doses of varicella vaccine administered 4 to 8 weeks apart.
• Laboratory Evidence of Immunity: Positive varicella IgG titer.
• Provider Verification of Disease: Diagnosis or verification of a history of varicella or herpes zoster by a licensed healthcare provider.

---

Tdap, Influenza, and COVID-19 Standards

---

Baseline & Occupational Tuberculosis (TB) Screening Standards

CDC published updated Tuberculosis Screening guidelines for healthcare personnel in 2019, revising traditional annual skin testing paradigms.

Baseline TB Screening Protocol

All newly hired HCP must undergo baseline screening before beginning patient care activities:

1. Individual Risk Assessment: Evaluate personal TB exposure risk factors.
2. Symptom Evaluation: Check for cough >3 weeks, hemoptysis, night sweats, fever, unexplained weight loss.
3. Diagnostic Screening Test: Perform an Interferon-Gamma Release Assay (IGRA) (e.g., QuantiFERON-TB Gold Plus, T-SPOT.TB) OR a Two-Step Tuberculin Skin Test (TST).

Rationale for the Two-Step TST Protocol

In individuals infected with Mycobacterium tuberculosis years ago, delayed-type hypersensitivity (DTH) memory may wane over time. A single initial TST may produce a false-negative result, but the antigen injection "boosts" immune memory.

• Step 1 TST: Administer 0.1 mL PPD intradermally. Read induration 48 to 72 hours later.
• If Step 1 is Positive (≥10 mm induration, or ≥5 mm in high-risk): Patient is considered infected (LTBI or active disease); evaluate with chest X-ray.
• If Step 1 is Negative: Administer Step 2 TST 1 to 3 weeks later. Read at 48 to 72 hours.
• If Step 2 is Positive: Interpreted as a Boosted Response (past latent infection recalled by first test), NOT a new conversion.
• If Step 2 is Negative: Confirmed baseline negative.

Annual & Post-Exposure Surveillance

• Routine Annual Testing Discontinued: Routine annual TB screening of low-to-medium risk HCP without known exposure is no longer recommended by the CDC.
• Post-Exposure Screening: Following known unprotected exposure to active TB, perform an immediate IGRA or TST (if baseline was negative). If negative, repeat testing 8 to 10 weeks post-exposure.